Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H
4th Department of Internal Medicine, National and Kapodistrian University of Athens, University General Hospital ATTIKON, Chaidari, Greece.
6th Department of Internal Medicine, Hygeia General Hospital, 4, Erythrou Stavrou Str & Kifisias, Marousi, Athens, Greece, PO:15123.
Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1305-1315. doi: 10.1007/s10096-017-2936-5. Epub 2017 Feb 16.
We report our experience using the double-carbapenem combination as salvage therapy for patients with untreatable infections caused by KPC-2- producing Klebsiella pneumoniae. A total of 27 patients in two institutions in Athens, Greece suffering from complicated urinary tract infections (16) with or without secondary bacteraemia (four and 12 respectively), primary (six) or catheter-related bloodstream infections (two), HAP or VAP (two) and external ventricular drainage infection (one) were treated exclusively with ertapenem and high-dose prolonged infusion meropenem because in-vitro active antimicrobials were unavailable (19) or failed (four) or were contraindicated (six). Most patients presented with severe infections with median APACHE II score of 17 and 11 of those patients (40.7%) had severe sepsis (five) or septic shock (six). The clinical and microbiological success was 77.8 and 74.1% respectively. Crude mortality was 29.6% with attributable mortality of 11.1%. Adverse events, none of them severe, were reported in four patients (14.8%). The double-carbapenem combination as an exclusive regimen represents a safe and valid salvage therapy for untreatable infections by extensively- or pandrug-resistant KPC-producing K.pneumoniae.
我们报告了使用双碳青霉烯联合疗法作为挽救疗法治疗由产KPC-2肺炎克雷伯菌引起的无法治疗的感染患者的经验。在希腊雅典的两个机构中,共有27例患者,分别患有复杂性尿路感染(16例),伴或不伴继发性菌血症(分别为4例和12例)、原发性(6例)或导管相关血流感染(2例)、医院获得性肺炎或呼吸机相关性肺炎(2例)以及脑室外引流感染(1例),这些患者仅接受了厄他培南和高剂量延长输注美罗培南治疗,原因是体外活性抗菌药物不可用(19例)、治疗失败(4例)或存在禁忌(6例)。大多数患者表现为严重感染,APACHE II评分中位数为17分,其中11例患者(40.7%)患有严重脓毒症(5例)或感染性休克(6例)。临床和微生物学成功率分别为77.8%和74.1%。粗死亡率为29.6%,归因死亡率为11.1%。4例患者(14.8%)报告了不良事件,但均不严重。双碳青霉烯联合疗法作为单一治疗方案,对于由广泛耐药或泛耐药产KPC肺炎克雷伯菌引起的无法治疗的感染而言,是一种安全有效的挽救疗法。